Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms

Franco Grimaldi, Nicola Fazio, Roberto Attanasio, Andrea Frasoldati, Enrico Papini, Nadia Cremonini, Mariavittoria Davi, Luigi Funicelli, Sara Massironi, Francesca Spada, Vincenzo Toscano, Annibale Versari, Michele Zini, Massimo Falconi, Kjell Oberg

Research output: Contribution to journalArticle

Abstract

Well-established criteria for evaluating the response to treatment and the appropriate follow-up of individual patients are critical in clinical oncology. The current evidence-based data on these issues in terms of the management of gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are unfortunately limited. This document by the Italian Association of Clinical Endocrinologists (AME) on the criteria for the follow-up of GEP-NEN patients is aimed at providing comprehensive recommendations for everyday clinical practice based on both the best available evidence and the combined opinion of an interdisciplinary panel of experts. The initial risk stratification of patients with NENs should be performed according to the grading, staging and functional status of the neoplasm and the presence of an inherited syndrome. The evaluation of response to the initial treatment, and to the subsequent therapies for disease progression or recurrence, should be based on a cost-effective, risk-effective and timely use of the appropriate diagnostic resources. A multidisciplinary evaluation of the response to the treatment is strongly recommended and, at every step in the follow-up, it is mandatory to assess the disease state and the patient performance status, comorbidities, and recent clinical evolution. Local expertise, available technical resources and the patient preferences should always be evaluated while planning the individual clinical management of GEP-NENs.

Original languageEnglish
JournalEndocrine, Metabolic and Immune Disorders - Drug Targets
DOIs
Publication statusE-pub ahead of print - Dec 13 2017

Fingerprint

Neoplasms
Professional Competence
Medical Oncology
Patient Preference
Therapeutics
Disease Progression
Comorbidity
Costs and Cost Analysis
Recurrence
Endocrinologists
methylamphotericin B

Keywords

  • Journal Article

Cite this

Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms. / Grimaldi, Franco; Fazio, Nicola; Attanasio, Roberto; Frasoldati, Andrea; Papini, Enrico; Cremonini, Nadia; Davi, Mariavittoria; Funicelli, Luigi; Massironi, Sara; Spada, Francesca; Toscano, Vincenzo; Versari, Annibale; Zini, Michele; Falconi, Massimo; Oberg, Kjell.

In: Endocrine, Metabolic and Immune Disorders - Drug Targets, 13.12.2017.

Research output: Contribution to journalArticle

@article{f4f94a117e3748fb8a20d29a38770b85,
title = "Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms",
abstract = "Well-established criteria for evaluating the response to treatment and the appropriate follow-up of individual patients are critical in clinical oncology. The current evidence-based data on these issues in terms of the management of gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are unfortunately limited. This document by the Italian Association of Clinical Endocrinologists (AME) on the criteria for the follow-up of GEP-NEN patients is aimed at providing comprehensive recommendations for everyday clinical practice based on both the best available evidence and the combined opinion of an interdisciplinary panel of experts. The initial risk stratification of patients with NENs should be performed according to the grading, staging and functional status of the neoplasm and the presence of an inherited syndrome. The evaluation of response to the initial treatment, and to the subsequent therapies for disease progression or recurrence, should be based on a cost-effective, risk-effective and timely use of the appropriate diagnostic resources. A multidisciplinary evaluation of the response to the treatment is strongly recommended and, at every step in the follow-up, it is mandatory to assess the disease state and the patient performance status, comorbidities, and recent clinical evolution. Local expertise, available technical resources and the patient preferences should always be evaluated while planning the individual clinical management of GEP-NENs.",
keywords = "Journal Article",
author = "Franco Grimaldi and Nicola Fazio and Roberto Attanasio and Andrea Frasoldati and Enrico Papini and Nadia Cremonini and Mariavittoria Davi and Luigi Funicelli and Sara Massironi and Francesca Spada and Vincenzo Toscano and Annibale Versari and Michele Zini and Massimo Falconi and Kjell Oberg",
note = "Copyright{\circledC} Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.",
year = "2017",
month = "12",
day = "13",
doi = "10.2174/1871530318666171213145803",
language = "English",
journal = "Endocrine, Metabolic and Immune Disorders - Drug Targets",
issn = "1871-5303",
publisher = "Bentham Science Publishers B.V.",

}

TY - JOUR

T1 - Assessment of Response to Treatment and Follow-Up in Gastroenteropancreatic Neuroendocrine Neoplasms

AU - Grimaldi, Franco

AU - Fazio, Nicola

AU - Attanasio, Roberto

AU - Frasoldati, Andrea

AU - Papini, Enrico

AU - Cremonini, Nadia

AU - Davi, Mariavittoria

AU - Funicelli, Luigi

AU - Massironi, Sara

AU - Spada, Francesca

AU - Toscano, Vincenzo

AU - Versari, Annibale

AU - Zini, Michele

AU - Falconi, Massimo

AU - Oberg, Kjell

N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

PY - 2017/12/13

Y1 - 2017/12/13

N2 - Well-established criteria for evaluating the response to treatment and the appropriate follow-up of individual patients are critical in clinical oncology. The current evidence-based data on these issues in terms of the management of gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are unfortunately limited. This document by the Italian Association of Clinical Endocrinologists (AME) on the criteria for the follow-up of GEP-NEN patients is aimed at providing comprehensive recommendations for everyday clinical practice based on both the best available evidence and the combined opinion of an interdisciplinary panel of experts. The initial risk stratification of patients with NENs should be performed according to the grading, staging and functional status of the neoplasm and the presence of an inherited syndrome. The evaluation of response to the initial treatment, and to the subsequent therapies for disease progression or recurrence, should be based on a cost-effective, risk-effective and timely use of the appropriate diagnostic resources. A multidisciplinary evaluation of the response to the treatment is strongly recommended and, at every step in the follow-up, it is mandatory to assess the disease state and the patient performance status, comorbidities, and recent clinical evolution. Local expertise, available technical resources and the patient preferences should always be evaluated while planning the individual clinical management of GEP-NENs.

AB - Well-established criteria for evaluating the response to treatment and the appropriate follow-up of individual patients are critical in clinical oncology. The current evidence-based data on these issues in terms of the management of gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) are unfortunately limited. This document by the Italian Association of Clinical Endocrinologists (AME) on the criteria for the follow-up of GEP-NEN patients is aimed at providing comprehensive recommendations for everyday clinical practice based on both the best available evidence and the combined opinion of an interdisciplinary panel of experts. The initial risk stratification of patients with NENs should be performed according to the grading, staging and functional status of the neoplasm and the presence of an inherited syndrome. The evaluation of response to the initial treatment, and to the subsequent therapies for disease progression or recurrence, should be based on a cost-effective, risk-effective and timely use of the appropriate diagnostic resources. A multidisciplinary evaluation of the response to the treatment is strongly recommended and, at every step in the follow-up, it is mandatory to assess the disease state and the patient performance status, comorbidities, and recent clinical evolution. Local expertise, available technical resources and the patient preferences should always be evaluated while planning the individual clinical management of GEP-NENs.

KW - Journal Article

U2 - 10.2174/1871530318666171213145803

DO - 10.2174/1871530318666171213145803

M3 - Article

C2 - 29237387

JO - Endocrine, Metabolic and Immune Disorders - Drug Targets

JF - Endocrine, Metabolic and Immune Disorders - Drug Targets

SN - 1871-5303

ER -